A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation.

@article{Kovarik2001APP,
  title={A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation.},
  author={John M. Kovarik and Bjorn A P Nashan and Peter Neuhaus and Pierre Alain Clavien and Christophe Gerbeau and Martica L Hall and Alexander Korn},
  journal={Clinical pharmacology and therapeutics},
  year={2001},
  volume={69 4},
  pages={201-9}
}
BACKGROUND Basiliximab is a high-affinity interleukin-2 receptor (CD25) chimeric monoclonal antibody used for immunoprophylaxis in organ transplantation. It was assessed in a randomized, double-blind, placebo-controlled efficacy trial in de novo liver allograft recipients who received 40 mg of basiliximab (20 mg on days 0 and 4) in addition to baseline immunosuppression with cyclosporine (INN, ciclosporin) microemulsion and corticosteroids. METHODS Serial blood samples (8.3 +/- 1.4 per… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Population pharmacokinetics of therapeutic monoclonal antibodies.

Clinical pharmacokinetics • 2010
View 4 Excerpts
Highly Influenced

Pharmacologic intervention for cancer-related dyspnea.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008

Similar Papers

Loading similar papers…